Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S McIntyre

Showing results (261-270 of 1,324) with videos related to

Pageof 133
Sort By:
The Journal of Clinical Psychiatry|June 6, 2009
Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literatureBenjamin I Goldstein, David E Kemp, Joanna K Soczynska, et al.
Nordic Journal of Psychiatry|August 27, 2016
Personalized medicine in psychiatryIda Kim Wium-Andersen, Maj Vinberg, Lars Vedel Kessing, et al.
Neuropsychiatric Disease and Treatment|December 28, 2018
Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studiesMichael E Thase, Emmanuelle Weiller, Peter Zhang, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|October 28, 2025
Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment ModelsJennifer Swainson, Elisa Brietzke, Atul Khullar, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|September 9, 2025
Repurposing glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of depression: A systematic review of preclinical, observational and clinical investigationsSophie Li, Sami George Sabbah, Angela T H Kwan, et al.
Sleep Medicine|September 5, 2013
Sleep architecture variation: a mediator of metabolic disturbance in individuals with major depressive disorderP A Kudlow, D S Cha, R W Lam, et al.
Expert Opinion on Pharmacotherapy|December 3, 2017
Efficacy of levomilnacipran extended release in treating major depressive disorderRenee-Marie Ragguett, Samantha J Yim, Peter T Ho, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 29, 2014
Inflamed moods: a review of the interactions between inflammation and mood disordersJoshua D Rosenblat, Danielle S Cha, Rodrigo B Mansur, et al.
Current Molecular Medicine|January 28, 2016
Fibromyalgia and Bipolar Disorder: Emerging Epidemiological Associations and Shared PathophysiologyB Bortolato, M Berk, M Maes, et al.
CNS Spectrums|October 18, 2021
Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustmentMichael Cronquist Christensen, Roger S McIntyre, Ioana Florea, et al.
Pageof 133

Showing results (261-270 of 1,324) with videos related to

Sort By:
Pageof 133
The Journal of Clinical Psychiatry|June 6, 2009
Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literatureBenjamin I Goldstein, David E Kemp, Joanna K Soczynska, et al.
Nordic Journal of Psychiatry|August 27, 2016
Personalized medicine in psychiatryIda Kim Wium-Andersen, Maj Vinberg, Lars Vedel Kessing, et al.
Neuropsychiatric Disease and Treatment|December 28, 2018
Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studiesMichael E Thase, Emmanuelle Weiller, Peter Zhang, et al.
Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie|October 28, 2025
Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment ModelsJennifer Swainson, Elisa Brietzke, Atul Khullar, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|September 9, 2025
Repurposing glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of depression: A systematic review of preclinical, observational and clinical investigationsSophie Li, Sami George Sabbah, Angela T H Kwan, et al.
Sleep Medicine|September 5, 2013
Sleep architecture variation: a mediator of metabolic disturbance in individuals with major depressive disorderP A Kudlow, D S Cha, R W Lam, et al.
Expert Opinion on Pharmacotherapy|December 3, 2017
Efficacy of levomilnacipran extended release in treating major depressive disorderRenee-Marie Ragguett, Samantha J Yim, Peter T Ho, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 29, 2014
Inflamed moods: a review of the interactions between inflammation and mood disordersJoshua D Rosenblat, Danielle S Cha, Rodrigo B Mansur, et al.
Current Molecular Medicine|January 28, 2016
Fibromyalgia and Bipolar Disorder: Emerging Epidemiological Associations and Shared PathophysiologyB Bortolato, M Berk, M Maes, et al.
CNS Spectrums|October 18, 2021
Vortioxetine 20 mg/day in patients with major depressive disorder: updated analysis of efficacy, safety, and optimal timing of dose adjustmentMichael Cronquist Christensen, Roger S McIntyre, Ioana Florea, et al.
Pageof 133